Drug Trial Radar · NCT03059537
Validation of Stimulated ∆FGF19 for Diagnosing Bile Acid Diarrhoea
Last checked: Nov 19, 2026Latest source record: Dec 12, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
71
Actual
Start
Mar 13, 2017
Primary completion
Nov 27, 2017
Study completion Nov 27, 2017
Sponsor
- Lead sponsor
- Lars Kristian MunckAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Feb 23, 2017
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Diagnostic
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study aims to validate a possible diagnostic test for bile acid diarrhoea prospectively compared to the SeHCAT scintigraphy. Fasting participants are given a standard meal and 1,250 mg chenodeoxycholic acid. The investigators measure fasting FGF19, bile acids species including 7-alpha-CHO and serial blood samples after the stimulation.
Conditions
- Bile Acid Malabsorption
Interventions
Oral chenodeoxycholic acid stimulationDrug
oral intake of chenodeoxycholic acid to stimulate the ileal bile acid transporter and farnesoid X receptor
Primary outcomes
What the sponsor says the trial is designed to measure.
- Negative predictive value of stimulated deltaFGF19Time frame: Individual data are collected within one week
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Aalborg University Hospital
Aalborg, Denmark
Aarhus University Hospital
Aarhus, Denmark
Zealand University Hopsital
Holbæk, Denmark
Hvidovre University Hospital
Hvidovre, Denmark
Zealand University Hospital
Køge, Denmark
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.